Weaving success stories together
In-licensed anti MUC-1 antibodies targeting several cancers
In-licensed Vibozilimod for treatment of auto-immune disorders
To identify inhibitors of a novel target to address PARP resistance in solid tumours
To evaluate anti-MUC-1 ADC in preclinical models
To investigate the effect of SPARC NCEs on modulating autophagy and inflammasome
Out-licensed Xelpros, Vibozilimod and Sezaby
Out-licensed Elepsia 1000mg and 1500mg
To identify targets and potential modulators of proteotoxicity in Alzheimer’s Disease
Out-licensed Brimonidine and Difluprednate
To study Abl kinase inhibitors in models of neurodegeneration
